Cerevel's Emraclidine Does Not Induce High Blood Pressure In Schizophrenia

 

• Cerevel Therapeutics Holdings, Inc. 
  CERE+22.3%+ Free Alerts
   announced results from the Phase 1 trial studying the effect of emraclidine on 24-hour ambulatory blood pressure over eight weeks in schizophrenia patients. 
• The trial's objective was to accurately characterize any potential blood pressure effect for both doses of emraclidine studied (10 and 30 mg QD).
• On the primary endpoint, emraclidine demonstrated a mean change from baseline at week eight in 24-hour ambulatory systolic blood pressure (SBP) of -2.7 mmHg for the 10 mg QD group and -0.4 mmHg for the 30 mg QD group. 
• The upper bound was -0.3 mmHg for the 10 mg QD group and 2.1 mmHg for the 30 mg QD group. 
• As a result, the trial ruled out an increase in blood pressure for both doses.
• The trial's secondary endpoints demonstrated findings consistent with the primary endpoint, corroborating the overall trial results. 
• Emraclidine was generally well-tolerated in this trial, with a side effect profile consistent with prior trials.
• This ambulatory blood pressure monitoring trial was designed in line with FDA guidance.

https://www.benzinga.com/general/biotech/22/12/30130123/data-shows-cerevels-emraclidine-does-not-induce-high-blood-pressure-in-schizophrenia-patients